Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Insilico Medicine Completes $60 Million Funding; Will Build Robotic Drug Discovery Lab

publication date: Jun 6, 2022

Insilico Medicine, a Hong Kong AI-based company, completed a $60 million Series D financing. The company said it will allocate part of the funds to build a fully automated, AI-driven robotic drug discovery laboratory and a fully robotic biological data factory, which will complement its large library of curated data assets. Insilico partners with other biopharma companies, using its AI discovery technology to discover drugs more quickly and at lower cost than traditional methods. Last week, it announced China approval to start trials of sn idiopathic pulmonary fibrosis therapy for its own portfolio. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital